Latest news with #ASTRO
News18
2 days ago
- Entertainment
- News18
IU's A Beautiful Person Track With Cha Eun Woo Is A Tale Of Self-Acceptance
Last Updated: A Beautiful Person was originally written and composed by the legendary Korean rock artist Shin Jung Hyun. South Korean actress-singer IU, aka Lee Ji Un, returned to music with the album Kkot-Galpi 3 (A Flower Bookmark 3). It is the third instalment of her popular cover series, where she reinterprets some beloved classics. She released the album on May 27, along with its title track, Never Ending Story, the reimagined version of BooHwal's legendary song. To create more hype regarding her third remake album, IU dropped a new music video for A Beautiful Person, feat. Balming Tiger, a B-side track of Kkot-Galpi 3. The MV features a cameo of none other than the K-pop star and ASTRO member Cha Eun Woo. The 3-minute and 42-second-long video was released on IU's official YouTube channel on Wednesday, May 28. A Beautiful Person, aka A Beauty, was originally written and composed by the legendary Korean rock artist Shin Jung Hyun and was one of the songs in his debut album. The single completely reinterpreted rock music in Korea back in the '70s. It was one of the biggest hits of Shin Jung Hyun's career and one of the best hits of the '70s. The music video opens with the birth of two babies at a hospital, a boy born as a being of light and a girl shrouded in darkness. The MV captures various moments from their lives, from childhood to adulthood. While the boy is so bright and special that everyone around admires him, the girl, on the other hand, always remains in the shadows. As the two grew older, the weight of being different became too much for both of them to handle. To fit in, the boy and the girl start to wear masks to hide their true self. One day, the boy coincidentally meets the girl, who, just like him, hides her identity behind a mask. Without saying much, the two form a deep bond. Then comes the powerful moment on the rooftop, where both unmasked themselves and embraced their true selves. The boy was played by Cha Eun Woo, and the girl by IU. In no time, the music video caught attention online, and fans started praising the concept behind it. The new album marks her return to the Kkot-Galpi series after eight years. Back in 2017, IU released Kkot-Galpi 2. Other tracks in the album are Never Ending Story, Red Sneakers, October 4th, and Last Scene (Feat. Wonstein), among others. First Published: May 29, 2025, 14:16 IST
Pink Villa
3 days ago
- Entertainment
- Pink Villa
'We'll meet again': SEVENTEEN's Seungkwan pens emotional note for ASTRO's Moonbin on old Instagram birthday post
SEVENTEEN's Seungkwan recently paid a deeply emotional tribute to his late friend Bini, aka ASTRO's Moonbin, for his birthday. Moonbin's birthday is celebrated on January 26, but Seungkwan shared a post a couple of days back. Though from different groups, their friendship stayed strong. Moonbin's sudden passing on April 19, 2023, deeply affected Seungkwan. In a heartfelt Instagram post, Seungkwan wrote, 'It's already been two years. How are you, my friend? I'm so late, sorry…' He confessed that he had written the message earlier but hesitated to post. Seungkwan shared the news of his latest solo release, 'You monitored it, right? Listen to it well.' He expressed regret that they never filmed fun challenges together, especially for his song Thunder. The K-pop singer said, 'It's a shame.. If we hadn't kept postponing things because we were tired." He continues, "We could've had so many precious videos left behind.' Reflecting on the love Moonbin left behind, Seungkwan shared that he found comfort in the heartfelt words the late idol said. The THUNDER singer said that due to Moonbin's words and behavior, their friendship was formed. Seungkwan shared that he often pauses to capture moments when the moon shines or dandelions bloom, feeling he's become more romantic. Seungkwan Talks About Memories Of The Moon Track He also thanked the ASTRO members for their work on the tribute song Memory of the Moon. He hoped Moonbin listened to it and found it touching. Seungkwan mentioned Eunwoo, Jinjin, Myungjun, Sanha and Rocky. He appreciated how hard they all worked. He was grateful to everyone who helped make the song. He hoped Moonbin would receive the tribute with the same warmth he always showed. Seungkwan's tribute closed with a simple but powerful message: 'I love you, Bin-ah.' Previously, Seungkwan shared a lengthy post with several snaps with Moonbin. Check below. ASTRO's Moonbin Sad Passing Moonbin, a member of the K-pop group ASTRO, passed away on April 19, 2023. He was 25 years old. His manager found him unresponsive at his apartment in Seoul. Police found no signs of foul play. It was ruled a suspected suicide. His sudden death shocked the K-pop industry and fans worldwide. Moonbin was known for his talent, kindness, and strong friendships. His passing left a deep impact on friends, fellow idols, and fans.
Yahoo
3 days ago
- Business
- Yahoo
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025 This Press Release removes references to preclinical data that has not yet been presented. Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses will present promising new preclinical results at the 2025 American Society for Radiation Oncology ("ASTRO") 67th Annual Meeting. The Company's latest research evaluates radiation-activated Rutherrin® versus radiation alone in the destruction of cancer cells in a number of preclinical cancer models. This data will be showcased at the 2025 ASTRO 67th Annual Meeting, the world's largest gathering of radiation oncology professionals, taking place in late September in San Francisco, California. ASTRO has selected the Theralase® abstract titled, "Rutherrin® Activated by Radiation Therapy Evaluated for Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models", for presentation in a scientific poster session. The study explores the potent anti-cancer effects of Rutherrin®—a ruthenium-based small molecule drug formulated with recombinant human transferrin for intravenous administration. Once activated by ionizing radiation through a process known as Radio Dynamic Therapy ("RDT"), Rutherrin® initiates a two-phase cancer-killing response: the generation of Reactive Oxygen Species ("ROS") for immediate cytotoxicity, followed by Immunogenic Cell Death ("ICD") to stimulate a durable immune response. The Preclinical Data Presented Will Evaluate: Selective Tumor Targeting: Rutherrin®'s accumulation in tumor tissues versus healthy cells. Blood-Brain Barrier Penetration: Concentrations in Glio Blastoma Multiforme ("GBM") tumors versus healthy brain tissue. Synergistic Mechanism: Combination of direct tumor cell destruction with immune activation. Survival Rates: Survival benefits compared to radiation therapy alone. Resistance: Inhibition of mechanisms associated with multidrug and radiation resistance. Adaptive Immune Activation: Induction of long-term immunity, based on resistance to tumor rechallenge. Mark Roufaiel, Ph.D., research scientist at Theralase® commented, "Results are expected to be highly encouraging. Rutherrin® is hypothesized to enhance the effectiveness of radiation therapy, but also activate a sustained immune response, offering a powerful, dual-action strategy against aggressive and treatment-resistant cancers." Arkady Mandel, M.D., Ph.D., Chief Scientific Officer of Theralase®, added, "Our focus is to bring this innovative platform to clinical application. Rutherrin® may represent a major advancement in oncologic treatment, potentially enabling radiation oncologists to dramatically improve patient outcomes. This research may provide a strong foundation for integrating Rutherrin® with existing cancer therapies to deliver more effective, long-lasting solutions." Roger DuMoulin-White, President and Chief Executive Officer of Theralase®, stated, "Based on the release of this compelling data in the fall, we are fully committed to completing GLP toxicology studies in 2025. This critical milestone will support the launch of clinical studies in early 2026 targeting GBM, lung, pancreatic, lymphoma and colorectal cancers. We're excited to continue advancing Rutherrin® toward commercialization and transforming cancer care." About Rutherrin® Rutherrin® is a patented formulation of Theralase®'s lead ruthenium-based small molecule (Ruvidar®) combined with recombinant human transferrin making it suitable for intravenous delivery. It has the ability to selectively accumulate in cancer cells versus healthy cells and when radiation-activated provide a one-two punch to cancer, by first destroying the cancer cell through oxidative stress and then activating the immune system for destruction of residual cancer cells. Rutherrin® is slated to enter clinical studies in early 2026 for the destruction of deadly cancers; including: brain, lung, pancreatic, colorectal and lymphoma. About Theralase® Technologies Inc. Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPAChief Financial Officer X 224khachey@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
4 days ago
- Entertainment
- Time of India
ASTRO's Cha Eunwoo is set for military enrollment, confirms date and time
ASTRO 's Cha Eunwoo is joining the list of male Korean celebrities that seem to be leaving for their mandatory military enlistment. The idol and actor is all set to commence his mandatory military service from July 28. Cha Eunwoo is all set for military In earlier news, it was shared by various news outlets that the pop star has officially sent in his application for the army military band. After officially getting his acceptance, the actor and idol has announced that he will be enlisting on July 28, as per reports from OSEN. The news came after the official notice of people who had passed the requirements for the band was released by the Military Manpower Administration. W hen the news of him applying for the band came out, his management agency also issued a statement saying, 'He applied for the Army Military Band at the end of March. He went through the proper procedures and completed the interview. We were informed that the results would be announced on the 29th. If accepted, although we didn't yet know the exact date, we understood that enlistment would take place sometime in July.' Fans were already expecting the enlistment date to be in July; however, the exact time was not confirmed until now. The agency has also issued a statement expressing the importance of privacy and how they will not be announcing when and where Cha Eunwoo will be departing for his military enlistment. Cha Eunwoo's latest projects Cha Eunwoo was last seen in the drama 'Wonderful World', where he played the lead role alongside popular actress Kim Nam Joo. After that, he also has another project lined up for a 2026 release. The K-drama titled 'The Wonder Fools' is currently in production and will see Cha Eunwoo and actress Park Eun Bin in the lead roles. Check out our list of the latest Hindi , English , Tamil , Telugu , Malayalam , and Kannada movies . Don't miss our picks for the best Hindi movies , best Tamil movies, and best Telugu films .
India Today
4 days ago
- Entertainment
- India Today
True Beauty actor Cha Eun-woo to enlist in military on July 28: Agency
Cha Eun-woo, member of the K-pop group ASTRO and one of the most popular and sought-after Korean actors, is set to begin his mandatory military service. Earlier this month, it was reported that he had applied to serve in the Army Military Band. On May 29, his agency Fantagio confirmed that he has been officially an official statement, Fantagio shared, "Cha Eun-woo applied to join the Army Military Band and received a final acceptance notice from the Military Manpower Administration today. He will enter the training centre on July 28 and undergo basic military training before fulfilling his duty in the Army Military Band."advertisementThe agency also noted that there will be no public events on enlistment day, adding, "To prevent safety accidents due to congestion on the day of enlistment, the location and time of Cha Eun-woo's enlistment will be kept private." Fantagio concluded with a message to fans, "We ask for your unsparing support and warm encouragement for Cha Eun-woo as he diligently fulfils his military duty and returns in good health."Best known for his roles in popular dramas like 'True Beauty', 'My ID is Gangnam Beauty', and 'A Good Day to Be a Dog', Cha Eun-woo has also made a mark as a solo artiste and variety show star. He most recently starred in the mystery-thriller 'Wonderful World' and is reportedly preparing for a solo fan-con tour in Asia, expected to wrap up before his enlistment. You May Also Like
